GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Cyclically Adjusted PB Ratio

Veracyte (Veracyte) Cyclically Adjusted PB Ratio : 2.83 (As of May. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Cyclically Adjusted PB Ratio?

As of today (2024-05-28), Veracyte's current share price is $20.80. Veracyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $7.35. Veracyte's Cyclically Adjusted PB Ratio for today is 2.83.

The historical rank and industry rank for Veracyte's Cyclically Adjusted PB Ratio or its related term are showing as below:

VCYT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.63   Med: 4.15   Max: 11.48
Current: 2.83

During the past years, Veracyte's highest Cyclically Adjusted PB Ratio was 11.48. The lowest was 2.63. And the median was 4.15.

VCYT's Cyclically Adjusted PB Ratio is ranked worse than
64.44% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.93 vs VCYT: 2.83

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Veracyte's adjusted book value per share data for the three months ended in Mar. 2024 was $14.637. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.35 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Veracyte Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Veracyte's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Cyclically Adjusted PB Ratio Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 11.46 4.39 3.97

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.14 3.34 3.97 3.02

Competitive Comparison of Veracyte's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Veracyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Cyclically Adjusted PB Ratio falls into.



Veracyte Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Veracyte's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=20.80/7.35
=2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Veracyte's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=14.637/131.7762*131.7762
=14.637

Current CPI (Mar. 2024) = 131.7762.

Veracyte Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.099 100.560 2.751
201409 2.147 100.428 2.817
201412 1.837 99.070 2.443
201503 1.555 99.621 2.057
201506 2.359 100.684 3.087
201509 2.090 100.392 2.743
201512 1.851 99.792 2.444
201603 1.555 100.470 2.040
201606 1.211 101.688 1.569
201609 1.074 101.861 1.389
201612 1.765 101.863 2.283
201703 1.575 102.862 2.018
201706 1.412 103.349 1.800
201709 1.260 104.136 1.594
201712 1.088 104.011 1.378
201803 0.874 105.290 1.094
201806 0.749 106.317 0.928
201809 1.959 106.507 2.424
201812 1.952 105.998 2.427
201903 2.018 107.251 2.479
201906 4.647 108.070 5.666
201909 4.732 108.329 5.756
201912 4.825 108.420 5.864
202003 4.608 108.902 5.576
202006 4.483 108.767 5.431
202009 7.312 109.815 8.774
202012 7.238 109.897 8.679
202103 14.490 111.754 17.086
202106 14.394 114.631 16.547
202109 15.586 115.734 17.746
202112 15.417 117.630 17.271
202203 15.192 121.301 16.504
202206 14.871 125.017 15.675
202209 14.610 125.227 15.374
202212 14.942 125.222 15.724
202303 14.938 127.348 15.457
202306 14.905 128.729 15.258
202309 14.440 129.860 14.653
202312 14.251 129.419 14.511
202403 14.637 131.776 14.637

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veracyte  (NAS:VCYT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Veracyte Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Veracyte's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines

From GuruFocus